Spectrum and treatment of anaerobic infections

Journal of Infection and Chemotherapy

Volumn 22, Issue 1, 2016, Pages 1-13

  Brook, Itzhak ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaerobes; Antibiotics; Antimicrobial resistance; Bacteroides fragilis; Infection

Indexed keywords

AMOXICILLIN DERIVATIVE; AMOXICILLIN PLUS SULBACTAM; AMPICILLIN PLUS CLAVULANATE; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; ERYTHROMYCIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TINIDAZOLE; TYGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ABDOMINAL INFECTION; ABSCESS; ACIDAMINOCOCCUS; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL ARTHRITIS; BRAIN ABSCESS; CENTRAL NERVOUS SYSTEM INFECTION; CERVICAL LYMPH NODE; CERVICAL LYMPHADENITIS; CLINICAL FEATURE; ENDOCARDITIS; ENDOSPORE-FORMING RODS AND COCCI; FEMALE GENITAL TRACT INFECTION; GAS GANGRENE; GRAM NEGATIVE ANAEROBIC COCCI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HEAD AND NECK INFECTION; HYPERBARIC OXYGEN; INFECTION PREVENTION; INTRACELLULAR KILLING; LUNG INFECTION; LYMPHADENITIS; MASTOIDITIS; MEDICATION COMPLIANCE; MEGASPHAERA; MENINGITIS; MONOTHERAPY; NONHUMAN; OSTEOMYELITIS; OTITIS MEDIA; PAROTITIS; PATIENT SAFETY; PHAGOCYTOSIS; POSTOPERATIVE INFECTION; REVIEW; RHINOSINUSITIS; SKIN INFECTION; SOFT TISSUE INFECTION; SUPPURATION; THROMBOPHLEBITIS; TONSILLITIS; TOOTH INFECTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VEILLONELLA; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIOLOGY; PATHOGENICITY;

ANTI-INFECTIVE AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; CEFOXITIN; CHLORAMPHENICOL; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; METRONIDAZOLE; MINOCYCLINE; PENICILLINS;

EID: 84976869937     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.10.010     Document Type: Review

References (93)

1. Hentges D.J. The anaerobic microflora of the human body. Clin Infect Dis 1993, 164:S175-S180.
2. Finegold S.M. Anaerobic infections in humans: an overview. Anaerobe 1995, 1:3-9.
3. Brook I. Pediatric anaerobic infection: diagnosis and management 2002, Marcel Dekker, New York. 3rd ed.
4. Jousimies-Somer H.R., Summanen P., Baron E.J., Citron D.M., Wexler H.M., Finegold S.M. Wadsworth-KTL. Anaerobic bacteriology manual 2002, Star Publishing, Belmont, CA. 6th ed.
5. L1 Coltella, Mancinelli L., Onori M., Lucignano B., Menichella D., Sorge R., et al. Russo C Advancement in the routine identification of anaerobic bacteria by MALDI-TOF mass spectrometry. Eur J Clin Microbiol Infect Dis 2013, 32:1183-1192.
6. Jousimies H., Summanen P. Recent taxonomic changes and terminology update of clinically significant anaerobic gram-negative bacteria (excluding spirochetes). Clin Infect Dis 2002, 35(Suppl. 1):S17-S21.
7. Brook I., Myhal L.A., Dorsey H.C. Encapsulation and pilus formation of Bacteroides sp. J Infect 1991, 25:251-257.
8. Hofstad T. Virulence determinants in non-spore-forming anaerobic bacteria. Scand J Infect Dis 1989, 15-24.
9. Brook I., Frazier E.H. Aerobic and anaerobic infection associated with malignancy. Support Care Cancer 1998, 6:125-131.
10. Le Moal G., Landron C., Grollier G., Bataille B., Roblot F., Nassans P., et al. Characteristics of brain abscess with isolation of anaerobic bacteria. Scand J Infect Dis 2003, 35:318-321.
11. Achermann Y., Goldstein E.J., Coenye T., Shirtliff M.E. Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev 2014, 27:419-440.
12. Brook I., Johnson N., Overturf G.D., Wilkins J. Mixed bacterial meningitis: a complication of ventriculo- and lumbo-peritoneal shunts. J Neurosurg 1977, 47:961-1104.
13. Bernardini G.L. Diagnosis and management of brain abscess and subdural empyema. Curr Neurol Neurosci Rep 2004, 4:448-456.
14. Brook I., Frazier E.H., Gher M.E. Aerobic and anaerobic microbiology of periodontal abscess. Oral Microbiol Immunol 1991, 6:123-125.
15. Tatakis D.N., Kumar P.S. Etiology and pathogenesis of periodontal diseases. Dent Clin North Am 2005, 49:491-516.
16. Brook I., Frazier E.H. Microbiology of mediastinitis. Arch Intern Med 1996, 156:333-336.
17. Brook I., Anthony B.V., Finegold S.M. Aerobic and anaerobic bacteriology of acute otitis media in children. J Pediatr 1978, 92:13-15.
18. Brook I., Yocum P., Shah K., Feldman B., Epstein S. The aerobic and anaerobic bacteriology of serous otitis media. Am J Otolaryngol 1983, 4:389-392.
19. Brook I. Prevalence of beta-lactamase-producing bacteria in chronic suppurative otitis media. Am J Dis Child 1985, 139:280-334.
20. Sweeney G., Picozzi G.I., Browning G.G. A quantitative study of aerobic and anaerobic bacteria in chronic suppurative otitis media. J Infect 1982, 5:47-55.
21. Brook I. The role of anaerobic bacteria in acute and chronic mastoiditis. Anaerobe 2005, 11:252-257.
22. Brook I. Aerobic and anaerobic bacteriology of cholesteatoma. Laryngoscope 1981, 91:250-335.
23. Lino Y., Hoshimi E., Tomioko S., Takasaka T., Kaneko Y., Yuasa R. Organic acids and anaerobic microorganisms in the contents of the cholesteatoma sac. Ann Otol Rhinol Laryngol 1983, 92:91-94.
24. Carenfelt C., Lundberg C. Purulent and non-purulent maxillary sinus secretions with respect to pO2, pCO2 and pH. Acta Otolaryngol 1977, 84:138-143.
25. Brook I., Frazier E.H., Foote P.A. Microbiology of the transition from acute to chronic maxillary sinusitis. J Med Microbiol 1996, 45:372-445.
26. Brook I., Yocum P. Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with chronic maxillary sinusitis. Ann Otol Rhinol Laryngol 1999, 108:293-335.
27. Nord C.E. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 1995, 20:1512-1524.
28. Brook I., Thompson D.H., Frazier E.H. Microbiology and management of chronic maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1994, 120:1317-1320.
29. Brook I. Microbiology and antimicrobial treatment of orbital and intracranial complications of sinusitis in children and their management. Int J Pediatr Otorhinolaryngol 2009, 73:1183-1186.
30. Brook I. Aerobic and anaerobic microbiology of suppurative sialadenitis. J Med Microbiol 2002, 51:526-529.
31. Brook I. Aerobic and anaerobic bacteriology of cervical adenitis in children. Clin Pediatr 1980, 19:693-776.
32. Brook I. The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis 1984, 6:601-607.
33. Brook I., Frazier E.H., Thompson D.H. Aerobic and anaerobic microbiology of peritonsillar abscess. Laryngoscope 1991, 101:289-292.
34. Brook I., Yocum P. Comparison of the microbiology of group A streptococcal and non-group A streptococcal tonsillitis. Ann Otol Rhinol Laryngol 1988, 97:243-246.
35. Brook I., Gober A.E. Bacteroides melaninogenicus its recovery from tonsils of children with acute tonsillitis. Arch Otolaryngol 1983, 109:818-820.
36. Helstrom S.A., Mandi P.A., Ripa T. Treatment of infectious mononucleosis with metronidazole. Scand J Infect Dis 1978, 10:7-9.
37. Puto A. Febrile exudative tonsillitis: viral or streptococcal. Pediatrics 1987, 80:6-12.
38. Brook I., Gober A.E. Treatment of non-streptococcal tonsillitis with metronidazole. Int J Pediatr Otorhinolaryngol 2005, 69:65-68.
39. Brook I., Foote P.A., Slots J., Jackson W. Immune response to Prevotella intermedia in patients with recurrent non-streptococcal tonsillitis. Ann Otol Rhinol Laryngol 1993, 102:113-116.
40. Brook I., Foote P.A., Slots J. Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with peritonsillar cellulitis and abscess. Clin Infect Dis 1995, 20(Suppl. 2):S220-S221.
41. Brook I., de Leyva F. Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with infectious mononucleosis. J Med Microbiol 1996, 44:131-134.
42. Brook I., de Leyva F. Microbiology of tonsillar surfaces in infectious mononucleosis. Arch Pediatr Adolesc Med 1994, 148:171-223.
43. Brook I., Yocum P., Friedman E.M. Aerobic and anaerobic bacteria in tonsils of children with recurrent tonsillitis. Ann Otol Rhinol Laryngol 1981, 90:261-333.
44. Tuner K., Nord C.E. Beta-lactamase-producing microorganisms in recurrent tonsillitis. Scand J Infect Dis 1983, 83-88.
45. Brook I., Shah K., Jackson W. Microbiology of healthy and diseased adenoids. Laryngoscope 2000, 110:994-1109.
46. Brook I., Yocum P. Quantitative measurement of beta-lactamase in tonsils of children with recurrent tonsillitis. Acta Otolaryngol 1984, 98:556-560.
47. Kaplan E.L., Johnson O.R. Eradication of group A streptococci from treatment failure of the upper respiratory tract by amoxicillin with clavulanate after oral penicillin. J Pediatr 1988, 113:400-403.
48. Brook I., Frazier E.H. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest 1993, 103:1502-1507.
49. Bartlett J.G., Gorbach S.L., Finegold S.M. The bacteriology of aspiration pneumonia. Am J Med 1974, 56:202-207.
50. Brook I. Bacterial colonization tracheobronchitis and pneumonia, following tracheostomy and long-term intubation in pediatric patients. Chest 1979, 70:420-424.
51. Brook I., Frazier E.H. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000, 49:827-830.
52. Bennion R.S., Thompson J.E., Baron E.J., Finegold S.M. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clin Ther 1990, 12(Suppl. C):31-44.
53. Pieracci F.M., Barie P.S., Bartlett J.G. Intra-abdominal infections. Curr Opin Crit Care 2007, 13:440-449.
54. Sheen-Chen S., Chen W., Eng H., Sheen C., Chou F., Cheng Y., et al. Bacteriology and antimicrobial choice in hepatolithiasis. Am J Infect Control 2000, 28:298-301.
55. Mongmorey R.S., Wilson S.E. Intra-abdominal abscesses: image-guided diagnosis and therapy. Clin Infect Dis 1996, 23:28-36.
56. Mazuski J.E., Sawyer R.G., Nathens A.B., DiPiro J.T., Schein M., Kudsk K.A., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002, 3:175-233.
57. Bohnen J.M.A., Mustard R.A., Oxholm S.E., Schouten B.D. APACHE II score and abdominal sepsis. Arch Surg 1988, 123:225-229.
58. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:133-164.
59. Bratzler D.W., Dellinger E.P., Olsen K.M., Perl T.M., Auwaerter P.G., Bolon M.K., et al. American Society of Health-System Pharmacists (ASHP); Infectious Diseases Society of America (IDSA); Surgical Infection Society (SIS); Society for Healthcare Epidemiology of America (SHEA). Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013, 14:73-156.
60. Sobel J.D. What's new in bacterial vaginosis and trichomoniasis?. Infect Dis Clin North Am 2005, 19:387-406.
61. Gradison M. Pelvic inflammatory disease. Am Fam Physician 2012, 85:791-796.
62. Walker C.K., Wiesenfeld H.C. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007, 44(Suppl. 3):S111-S122.
63. Brook I., Frazier E.H. Clinical features and aerobic and anaerobic microbiological characteristics of cellulitis. Arch Surg 1995, 130:786-792.
64. Brook I., Finegold S.M. Aerobic and anaerobic microbiology of cutaneous abscesses in children. Pediatrics 1981, 67:891-895.
65. Brook I. Secondary bacterial infections complicating skin lesions. J Med Microbiol 2002, 51:808-812.
66. Meislin H.W., Lerner S.A., Graves M.H., McGehee M.D., Kocka F.E., Morello J.A., et al. Cutaneous abscesses: anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 1977, 97:145-150.
67. Brook I., Frazier E.H. Clinical and microbiological features of necrotizing fasciitis. J Clin Microb 1995, 33:2382-2387.
68. Merriam C.V., Fernandez H.T., Citron D.M., Tyrrell K.L., Warren Y.A., Goldstein E.J. Bacteriology of human bite wound infections. Anaerobe 2003, 9:83-86.
69. Brook I., Frazier E.H. Anaerobic osteomyelitis and arthritis in a military hospital: a 10-year experience. Am J Med 1993, 94:21-28.
70. Brook I. The role of anaerobic bacteria in bacteremia. Anaerobe 2010, 16:183-189.
71. Raff M.J., Melo J.C. Anaerobic osteomyelitis. Medicine 1978, 57:83-103.
72. Dorsher C.W., Rosenblatt J.E., Wilson W.R., Ilstrup D.M. Anaerobic bacteremia: decreasing rate over a 15-year period. Rev Infect Dis 1991, 16:633-636.
73. Lassmann B., Gustafson D.R., Wood C.M., Rosenblatt J.E. Reemergence of anaerobic bacteremia. Clin Infect Dis 2007, 44:895-900.
74. Cimşit M., Uzun G., Yildiz S. Hyperbaric oxygen therapy as an anti-infective agent. Expert Rev Anti Infect Ther 2009, 7:1015-1026.
75. Snydman D.R., Jacobus N.V., McDermott L.A., Golan Y., Goldstein E.J., Harrell L., et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 2011, 17:147-151.
76. Sherwood J.E., Fraser S., Citron D.M., Wexler H., Blakely G., Jobling K., et al. Multidrug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 2011, 17:152-155.
77. Centers for Disease Control and Prevention (CDC) Multidrug-resistant Bacteroides fragilis-Seattle, Washington. MMWR Morb Mortal Wkly Rep 2013, 2013(62):694-696.
78. Sutter V.L., Finegold S.M. Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother 1976, 10:736-752.
79. Brook I., Wexler H.M., Goldstein E.J. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013, 26:526-546.
80. Mastrantonio P., Cardines R., Spigaglia P. Oligonucleotide probes for detection of cephlosporinases among Bacteroides strains. Antimicrob Agents Chemother 1996, 40:1014-1016.
81. Aldridge K.E., Sanders C.V. Susceptibility trending of blood isolates of the Bacteroides fragilis group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole. Anaerobe 2002, 8:301-305.
82. Solomkin J.S., Mazuski J.E., Bradley J.S., Rodvold K.A., Goldstein E.J., Baron E.J., et al. Diagnosis and management of complicated intraabdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:133-164.
83. Liu C.Y., Huang Y.T., Liao C.H., Yen L.C., Lin H.Y., Hsueh P.R. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008, 52:3161-3168.
84. Hoellman D.B., Kelly L.M., Credito K., Anthony L., Ednie L.M., Jacobs M.R., et al. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother 2002, 46:220-224.
85. Aldridge K.E., Ashcraft D., Cambre K., Pierson C.L., Jenkins S.G., Rosenblatt J.E. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001, 45:1238-1243.
86. Goldstein E.J.C., Citron D.M., Merriam C.V. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999, 43:1469-1474.
87. Sanai Y., Persson G.R., Starr J.R., Luis H.S., Bernardo M., Leitao J., et al. Presence and antibiotic resistance of Porphyromonas gingivalis, Prevotella intermedia, and Prevotella nigrescens in children. J Clin Periodontol 2002, 29:929-934.
88. King A., Downes J., Nord C.E., Phillips I., European Study Group Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic gram-negative bacilli in Europe. Clin Microbiol Infect 1999, 5:404-416.
89. Nord C.E., Oprica C. Antibiotic resistance in Propionibacterium acnes, microbiological and clinical aspects. Anaerobe 2006, 12:207-210.
90. Townsend M.L., Pound M.W., Drew R.H. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract 2006, 60:1662-1667.
91. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H.T. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006, 50:3507-3513.
92. Stein G.E., Goldstein E.J. Fluoroquinolones and anaerobes. Clin Infect Dis 2006, 42:1598-1607.
93. Finch R.G. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 1996, 51:31-37.